Compositions and methods for reducing the transmissivity of illnesses using an oral delivery system

Abstract

Methods for prophylactic and anti-transmissivity uses of an anti-microbial composition are disclosed. The methods comprise the step of administering to a human an amount of a composition having a first ingredient being xylitol; a second ingredient comprised of a glycyrrhizin-protargin-quercetin complex, in addition to formula stabilizing ingredients of glycerol monolaurate, grapefruit seed extract; vitamin C (ascorbic acid), aloe emodin, curcumin, 1,8-cineole, zinc, quinine, flavoring, and an acceptable preservative for use in an oral application. When administered the composition is effective in reducing the incidence of contracting an illness or to prophylactically help prevent transmission of an illness into the or cavity and respiratory tract.

What is claimed is: 
     
         1 . A pharmaceutically acceptable formulation comprising:
 xylitol;   silver nanoparticles;   glycyrrhizin; and   quercetin.   
     
     
         2 . The pharmaceutically acceptable formulation according to  claim 1 , further comprising: ascorbic acid; grapefruit seed extract; monolaurin; eucalyptol; emodin or aloe emodin; zinc citrate; and quinine. 
     
     
         3 . The pharmaceutically acceptable formulation according to  claim 1 , wherein:
 the pharmaceutically acceptable formulation is an oral or intranasal liquid;   the xylitol is present in an amount of at least 1 g/100 ml;   the silver nanoparticles are present in an amount of at least 0.001 g/100 ml;   the glycyrrhizin is present as glycyrrhizic acid in an amount of at least 0.1 g/100 ml; and   the quercetin is present in an amount of at least 0.1 g/100 ml.   
     
     
         4 . The pharmaceutically acceptable formulation according to  claim 1 , wherein:
 the pharmaceutically acceptable formulation is an oral or intranasal liquid;   the xylitol is present in an amount of between 1-10 g/100 ml;   the silver nanoparticles are present in an amount of between 0.001-0.020 g/100 ml;   the glycyrrhizin is present as glycyrrhizic acid in an amount of between 0.1-0.5 g/100 ml; and   the quercetin is present in an amount of between 0.1-5 g/100 ml.   
     
     
         5 . The pharmaceutically acceptable formulation according to  claim 4 , further comprising ascorbic acid in an amount of between 0.1-3 g/100 ml. 
     
     
         6 . The pharmaceutically acceptable formulation according to  claim 4 , further comprising grapefruit seed extract in an amount of between 0.1-0.5 g/100 ml. 
     
     
         7 . The pharmaceutically acceptable formulation according to  claim 4 , further comprising monolaurin in an amount of between 0.1-0.5 g/100 ml. 
     
     
         8 . The pharmaceutically acceptable formulation according to  claim 4 , further comprising eucalyptol in an amount of between 0.10-0.5 g/100 ml. 
     
     
         9 . The pharmaceutically acceptable formulation according to  claim 4 , further comprising emodin in an amount of between 0.01-0.9 g/100 ml. 
     
     
         9 . The pharmaceutically acceptable formulation according to  claim 4 , further comprising aloe emodin in an amount of between 0.01-0.9 g/100 ml. 
     
     
         10 . The pharmaceutically acceptable formulation according to  claim 4 , further comprising zinc citrate in an amount of between 1-3 g/100 ml. 
     
     
         11 . The pharmaceutically acceptable formulation according to  claim 4 , further comprising quinine in an amount of between 0.005-0.2 g/100 ml. 
     
     
         12 . A method for reducing the transmissivity of an airborne bacteria or virus, comprising orally or intranasally administering to a subject a pharmaceutically acceptable formulation comprising xylitol; silver nanoparticles; glycyrrhizin; and quercetin. 
     
     
         13 . The method according to  claim 12 , wherein the pharmaceutically acceptable formulation further comprises: ascorbic acid; grapefruit seed extract; monolaurin; eucalyptol; emodin or aloe emodin; zinc citrate; and quinine. 
     
     
         14 . The method according to  claim 12 , wherein:
 the pharmaceutically acceptable formulation is an intranasal liquid;   the xylitol is present in an amount of at least 1 g/100 ml;   the silver nanoparticles are present in an amount of at least 0.001 g/100 ml;   the glycyrrhizin is present as glycyrrhizic acid in an amount of at least 0.1 g/100 ml; and   the quercetin is present in an amount of at least 0.1 g/100 ml.   
     
     
         15 . The method according to  claim 14 , wherein:
 the xylitol is present in an amount of between 1-10 g/100 ml;   the silver nanoparticles are present in an amount of between 0.001-0.020 g/100 ml;   the glycyrrhizin is present as glycyrrhizic acid in an amount of between 0.1-0.5 g/100 ml; and   the quercetin is present in an amount of between 0.1-5 g/100 ml.   
     
     
         16 . The method according to  claim 12 , further comprising determining an infection of the subject with the airborne bacteria or virus, and selectively intranasally administering the pharmaceutically acceptable formulation as a nasal spray in dependence on the determined infection. 
     
     
         17 . The method according to  claim 16 , wherein the pathogen causing the determined infection is SARS-Cov2. 
     
     
         18 . A pharmaceutical formulation in a light-proof multidose container, each dose comprising:
 1-15 mg soluble oleoresin turmeric,   1-10% xylitol,   0.1-0.5% glycyrrhizic acid,   0.1-5% quercetin,   1-30 mg ascorbic acid,   0.1-0.5% grapefruit seed extract,   0.1-0.5% monolaurin,   0.01-0.5% eucalyptol,   0.01-0.9% emodin or aloe emodin, 1-3% zinc citrate,   5-200 ppm quinine,   at least one of potassium sorbate and benzalkonium chloride as a preservative, and   1-20% ethanol,   in an aqueous delivery system.   
     
     
         19 . The pharmaceutical formulation according to  claim 18 , further comprising 1-20 μg silver nanoparticles. 
     
     
         20 . The pharmaceutical formulation according to  claim 19 , further comprising thymol, a pharmaceutically acceptable flavoring agent, wherein the aqueous delivery system is adjusted to have a pH between pH 3.0 and pH 4.5.